STAT-3 inhibitors: State of the art and new horizons for cancer treatment

Current Medicinal Chemistry

Volumn 18, Issue 16, 2011, Pages 2359-2375

  Lavecchia, A ^a   Di Giovanni, C ^a   Novellino, E ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antitumor therapeutics; Cancer; Molecular targeted therapy; Small molecule inhibitors; STAT3

Indexed keywords

3,5,4' TRIHYDROXYSTILBENE; ANTINEOPLASTIC AGENT; CPA 1; CPA 7; E 804; GALIELLALACTONE; INDIRUBIN; IS 3295; ISS 610; JSI 124; LLL 12; NSC 135075; S 31201; S 31M2001; S 3I201; STAT3 INHIBITOR; STAT3 PROTEIN; STX 0119; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION;

ANIMALS; HUMANS; NEOPLASMS; ORGANIC CHEMICALS; ORGANOMETALLIC COMPOUNDS; PEPTIDES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 79957940748     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795843218     Document Type: Article

References (110)

1. Darnell, J.E.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, 264(5164), 1415-1421. (Pubitemid 24217131)
2. Levy, D.E.; Darnell, J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol., 2002, 3(9),651-662. (Pubitemid 34987786)
3. Mertens, C.; Darnell, J.E. Snapshot: JAK-STAT signaling. Cell, 2007, 131(3), 612-612.e1.
4. Sehgal, P.B.; Levy, D.E.; Hirano, T. Signal transducers and activators of transcription: activation and biology; Kluwer Academic Press: Dordrecht, 2003.
5. Shuai, K.; Horvath, C.M.; Huang, L.H.; Qureshi, S.A.; Cowburn, D.; Darnell, Jr. J.E. Interferon activation of the transcription factor Stat91 involves dimerization through SH-2 phosphotyrosyl peptide interactions. Cell, 1994, 76(5), 821-828. (Pubitemid 24085320)
6. Darnell, J.E. Jr. STATs and gene regulation. Science, 1997, 277(5332), 1630-1635. (Pubitemid 27446219)
7. Sehgal, P.B. Paradigm shifts in the cell biology of STAT signaling. Semin. Cell Dev. Biol., 2008, 19(4), 329-340.
8. Liu, L.; McBride, K.M.; Reich, N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc. Natl. Acad. Sci. USA, 2005, 102(23), 8150-8155. (Pubitemid 40800058)
9. Leong, P.L.; Xi, S.; Drenning, S.D.; Dyer, K.F.; Wentzel, A.L.; Lerner, E.C.; Smithgall, T.E.; Grandis, J.R. Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene, 2002, 21(18), 2846-2853. (Pubitemid 34499382)
10. Tan, S.H.; Nevalainen, M.T. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr. Relat. Cancer, 2008, 15(2), 367-390. (Pubitemid 351880829)
11. Schaefer, T.S.; Sanders, L.K.; Park, O.K.; Nathans, D. Functional differences between Stat3alpha and Stat3beta. Mol. Cell Biol., 1997, 17(9), 5307-5316.
12. John, S.; VinKemeier, U.; Soldaini, E.; Darnell, J. E. Jr.; Leonard, W.J. The significance of tetramerization in promoter recruitment by STAT5. Mol. Cell Biol., 1999, 19(3), 1910-1918. (Pubitemid 29098249)
13. Collum, R.G.; Brutsaert, S.; Lee, G.; Schindler, C.A. Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc. Natl. Acad. Sci. USA, 2000, 97(18), 10120-10125.
14. Horvath, C.M. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem. Sci., 2000, 25(10), 496-502.
15. Yu, H.; Jove, R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer, 2004, 4(2), 97-105. (Pubitemid 38198738)
16. Bromberg, J.F.; Wrzeszczynska, M.H.; Devgan, G.; Zhao, Y.; Pestell, R.G.; Albanese, C.; Darnell, J.E. Jr. Stat3 as an oncogene. Cell, 1999, 98(3), 295-303. (Pubitemid 29380565)
17. Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res., 2008, 18(2), 254-267. (Pubitemid 351206162)
18. Catlett-Falcone, R.; Landowski, T.H.; Oshiro, M.M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernández-Luna, J.L.; Nuñez, G.; Dalton, W.S.; Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999, 10(1), 105-115. (Pubitemid 29077388)
19. Epling-Burnette, P.K.; Liu, J.H.; Catlett-Falcone, R.; Turkson, J.; Oshiro, M.; Kothapalli, R.; Li, Y.; Wang, J.M.; Yang-Yen, H.F.; Karras, J.; Jove, R.; Loughran, T.P. Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest., 2001, 107(3), 351-362.
20. Lou, W.; Ni, Z.; Dyer, K.; Tweardy, D.J.; Gao, A.C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 2000, 42(3), 239-242. (Pubitemid 30080423)
21. Garcia, R.; Yu, C.L.; Hudnall, A.; Catlett, R.; Nelson, K.L.; Smithgall, T.; Fujita, D.J.; Ethier, S.P.; Jove, R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Diff., 1997, 8(12), 1267-1276. (Pubitemid 28008723)
22. Garcia, R.; Bowman, T.L.; Niu, G.; Yu, H.; Minton, S.; Muro-Cacho, C.A.; Cox, C.E.; Falcone, R.; Fairclough, R.; Parsons, S.; Laudano, A.; Gazit, A.; Levitzki, A.; Kraker, A.; Jove, R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene, 2001, 20(20), 2499-2513. (Pubitemid 32531347)
23. Niu, G.; Bowman, T.; Huang, M.; Shivers, S.; Reintgen, D.; Daud, A.; Chang, A.; Kraker, A.; Jove, R.; Yu, H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene, 2002, 21(46), 7001- 7010. (Pubitemid 35252974)
24. Chan, K.S.; Carbajal, S.; Kiguchi, K.; Clifford, J.; Sano, S.; Di Giovanni, J. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res., 2004, 64(7), 2382-2329.
25. Song, J.I.; Grandis, J.R. STAT signaling in head and neck cancer. Oncogene, 2000, 19(21), 2489-2495. (Pubitemid 30339204)
26. Song, L.; Morris, M.; Bagui T.; Lee, F.Y.; Jove, R.; Haura, E.B. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res., 2006, 66(11), 5542-5548. (Pubitemid 43927102)
27. Grandis, J.R.; Zeng, Q.; Drenning, S.D. Epidermal growth factor receptor- mediated stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope, 2000, 110(5 Pt 1), 868-874. (Pubitemid 30266269)
28. Nam, S.; Kim, D.; Cheng, J.Q.; Zhang, S.; Lee, J.H.; Buettner, R.; Mirosevich, J.; Lee, F.Y.; Jove, R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res., 2005, 65(20), 9185-9189. (Pubitemid 41507982)
29. Trevino, J.G.; Gray, M.J.; Nawrocki, S.T.; Summy, J.M.; Lesslie, D.P.; Evans, D.B.; Sawyer, T.K.; Shakespeare, W.C.; Watowich, S.S.; Chiao, P.J.; McConkey, D.J.; Gallick, G.E. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis, 2006, 9(2), 101-110. (Pubitemid 44440555)
30. Sinibaldi, N.; Wharton, W.; Turkson, J.; Bowman, T.; Pledger,W.J.; Jove, R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene, 2000, 19(48), 5419-5427. (Pubitemid 32000908)
31. Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W,; Kondo,Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene, 2007, 26(17), 2435-2444. (Pubitemid 46597261)
32. Bhattacharya, S.; Ray, R.M.; Johnson, L.R. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem. J., 2005, 392(Pt 2), 335-344. (Pubitemid 41796522)
33. Gritsko, T.; Williams, A.; Turkson, J.; Kaneko, S.; Bowman, T., Huang, S., Nam, S.; Eweis, I.; Diaz, N.; Sullivan, D.; Yoder, S.; Enkemann, S.; Eschrich, S.; Lee, J.H.; Beam, C.A.; Cheng, J.; Minton, S.; Muro-Cacho, C.A.; Jove, R. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res., 2006, 12(1), 11-19. (Pubitemid 43166170)
34. Diaz, N.; Minton, S.; Cox, C.; Bowman, T.; Gritsko, T.; Garcia, R.; Eweis, I.; Wloch, M.; Livingston, S.; Seijo, E.; Cantor, A.; Lee, J.H.; Beam, C.A.; Sullivan, D.; Jove, R.; Muro-Cacho, C.A. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res. 2006, 12(1), 20-28. (Pubitemid 43166171)
35. Park S.; Kim, D.; Kaneko, S.; Szewczyk, K.M.; Nicosia, S.V.; Yu, H.; Jove, R.; Cheng, J.Q. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J. Biol. Chem., 2005, 280(47), 38932-38941. (Pubitemid 41713842)
36. Niu, G.; Wright, K.L.; Ma, Y.; Wright, G.M.; Huang, M.; Irby, R.; Briggs, J.; Karras, J.; Cress, W.D.; Pardoll, D.; Jove, R.; Chen, J.; Yu, H. Role of Stat3 in regulating p53 expression and function. Mol. Biol. Cell , 2005, 25(17), 7432-7440. (Pubitemid 41170107)
37. Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; Heller, R.; Ellis, L.M.; Karras, J.; Bromberg, J.; Pardoll, D.; Jove, R.; Yu, H. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene, 2002, 21(13), 2000-2008. (Pubitemid 34270888)
38. Xu, Q.; Briggs, J.; Park, S.; Niu, G.; Kortylewski, M.; Zhang, S.; Gritsko, T.; Turkson, J.; Kay, H.; Semenza, G.L.; Cheng, J.Q.; Jove, R. Yu, H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene, 2005, 24(36), 5552-5560. (Pubitemid 43119350)
39. Gray, M.J.; Zhang, J.; Ellis, L.M.; Semenza, G.L.; Evans, D.B.; Watowich, S.S.; Gallick, G.E. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene, 2005, 24(19), 3110-3120. (Pubitemid 40695080)
40. Itoh, M.; Murata, T.; Suzuki, T.; Shindoh, M.; Nakajima, K.; Imai, K.; Yoshida, K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene, 2006, 25(8), 1195-1204.
41. Xie, T.X.; Wei, D.; Liu, M.; Gao, A.C.; Ali-Osman, F.; Sawaya, R.; Huang, S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene, 2004, 23(20), 3550-3560. (Pubitemid 38658421)
42. Yu, H.; Jove, R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 2004, 4(2), 97-105. (Pubitemid 38198738)
43. Yue, P.; Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs, 2009, 18(1), 45-56.
44. Becker, S.; Groner, B.; Müller, C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature, 1998, 394(6689), 145-151. (Pubitemid 28325960)
45. McMurray, J. S. A new small molecule Stat 3 inhibitor. Chem. Biol., 2006, 13(11), 123-1124.
46. Jing, N.; Tweardy, D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs, 2005, 16(6), 601-607. (Pubitemid 40863092)
47. Blaskovich MA, Sun J, Cantor A, Turkson, J.; Jove, R.; Sebti, M.S. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res., 2003, 63(15), 1270-1279. (Pubitemid 36348705)
48. Sun, J.; Blaskovich, M.A.; Jove, R.; Livingston, S.K.; Coppola, D.; Sebti, S.M. Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity. Oncogene, 2005, 24(20), 3236-3245. (Pubitemid 40695105)
49. Nam, S.; Buettner, R.; Turkson, J.; Kim, D.; Cheng, J.Q.; Muehlbeyer, S.; Hippe, F.; Vatter, S.; Merz K.H.; Eisenbrand, G.; Jove, R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. USA, 2005, 102(17), 5998-6003. (Pubitemid 40594244)
50. Turkson, J.; Ryan, D.; Kim, J.S.; Zhang. Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.M. Hamilton, A.D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem., 2001, 276(30), 45443-45455.
51. Turkson, J.; Kim, J.S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A.D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther., 2004, 3(3), 261-269. (Pubitemid 39193701)
52. Turkson, J.; Zhang, S.; Palmer, J.; Kay, H.; Stanko, J.; Mora, L.B.; Sebti, S.; Yu, H.; Jove, R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther., 2004, 3(3), 1533-1542. (Pubitemid 40136708)
53. Turkson, J.; Zhang, S.; Mora, L.B.; Burns, A.; Sebti, S.; Jove, R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem., 2005, 280(38), 32979-32998.
54. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell Biol., 1998, 18(5), 2545-2552. (Pubitemid 28183424)
55. Ren, Z.; Cabell, L.A.; Schaefera, S.T.; McMurray, S.J. Identification of a High-Affinity Phosphopeptide Inhibitor of Stat3. Bioorg. Med. Chem. Lett., 2003, 13(4), 633-636. (Pubitemid 36298456)
56. Stahl, N.; Farruggella, T. J.; Boulton, T. J.;. Zhong, Z.; Darnell, J. E.; Yancopoulos, G.D.; Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science, 1995, 267(5202), 1349-1353.
57. Coffer, P.; Kruijer, W. EGF Receptor Deletions Define a Region Specifically Mediating Stat Transcription Factor Activation. Biochem. Biophys. Res. Commun., 1995, 210(1), 74-81.
58. Weber-Nordt, M.; Riley, J.K.; Greenlund, A.C.; Moore, K.W.; Darnell, J.E.; Schreiber, R. D. Stat3 recruitment by two distinct ligand-induced, tyrosinephosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem., 1996, 271(5202), 27954-27961. (Pubitemid 26367376)
59. Chakraborty, A.; Dyer, K.F.; Cascio, M.; Mietzner, T.A.; Tweardy, D.J. Identification of a Novel Stat3 Recruitment and Activation Motif Within the Granulocyte Colony-Stimulating Factor Receptor. Blood, 1999, 93(1), 15-24 (Pubitemid 29019383)
60. Park, O.K.; Schaefer, L.K.; Wang, W.; Schaefer, T.S. Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms. J. Biol. Chem., 2000, 275(13), 32244-32249.
61. Schust, J.; Berg, T. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal. Biochem., 2004, 330(1), 114-118. (Pubitemid 38746981)
62. Gunning, P.T.; Katt, W.P.; Glenn, M.; Siddiquee, K.; Kim, J.S.; Jove, R.; Sebti, S.M.; Turkson, J.; Hamilton, A.D. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorg. Med. Chem. Lett., 2007, 17(7), 1875-1878. (Pubitemid 46367686)
63. Mao, X.; Ren, Z.; Parker, G.N.; Sondermann, H.; Pastorello, M.A.; Wang, W.; McMurray, J.S.; Demeler, B.; Darnell, J.E. Jr.; Chen, X. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol. Cell., 2005, 17(6),761-771. (Pubitemid 40386938)
64. Siddiquee, K.A.Z.; Gunning, P.T.; Glenn, M.P.; Katt, W.P.; Zhang, S.; Schrock, C.; Sebti, S.M.; Jove, R.; Hamilton, A.D.; Turkson, J. An oxazolebased small-molecule STAT3 inhibitor modulates STAT3 stability and processing and induces antitumor cell effects. ACS Chem. Biol., 2007, 2(12), 787-797.
65. Coleman, D.R.IV; Ren, Z.; Mandal, P.K.; Cameron, A.G.; Dyer, G.A.; Muranjan, S.; Campbell, M.; Chen, X.; McMurray, J.S. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J. Med. Chem., 2005, 48(21), 6661-6670. (Pubitemid 41504722)
66. Mandal, P.K.; Heard, P.A.; Ren, Z.; Chen, X.; McMurray, J.S. Solid-phase synthesis of Stat3 inhibitors incorporating Ocarbamoylserine and Ocarbamoylthreonine as glutamine mimics. Bioorg. Med. Chem. Lett., 2007, 17(3), 654-656. (Pubitemid 46108571)
67. Mandal, P.K.; Limbrick, D.; Coleman, D.R.; Dyer, G.A.; Ren, Z.; Birtwistle, J.S.; Xiong, C.; Chen, X.; Briggs, J.M.; McMurray, J.S. Conformationally constrained peptidomimetic inhibitors of signal transducer and activator oftranscription 3: evaluation and molecular modeling. J. Med. Chem., 2009, 52(8), 2429-2442.
68. Gomez, C.; Bai, L.; Zhang, J.; Nikolovska-Coleska, Z.; Chen, J.; Yi, H.; Wang, S. Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(6), 1733-1736.
69. Chen, J.; Bai, L.; Bernard, D.; Nikolovska-Coleska, Z.; Gomez, C.; Zhang, J.; Yi, H.; Wang, S. Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors. Med. Chem. Lett., 2010, 1(2), 85-89.
70. Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA, 2005, 102(13), 4700-4705. (Pubitemid 40471517)
71. Chen, C.L.; Loy, A.; Cen, L.; Chan, C.; Hsieh, F.C.; Cheng, G.; Wu, B.; Qualman, S.J.; Kunisada, K.; Yamauchi-Takihara, K.; Lin, J. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer, 2007, 7(111).
72. Bhasin, D.; Cisek, K.; Pandharkar, T.; Regan, N.; Li, C.; Pandit, B.; Lin, J.; Li, P.K. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(1), 391-395.
73. Lin, L.; Hutzen, B.; Li, P. K.; Ball, S.; Zuo, M.; Deangelis, S.; Foust, E.; Sobo, M.; Friedman, L.; Bhasin, D.; Cen, L.; Li, C.; Lin, J. A Novel Small Molecule, LLL12, Inhibits STAT3 Phosphorylation and Activities and Exhibits Potent Growth-Suppressive Activity in Human Cancer Cells. Neoplasia, 2010, 12(1), 39-50.
74. Hao, W.; Hu, Y.; Niu, C.; Huang, X.; Chang, C.P.B.; Gibbons, J.; Xu, J. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg. Med. Chem. Lett., 2008, 18(18), 4988-4992.
75. Siddiquee, K.; Zhang, S.; Guida, W.C.; Blaskovich, M.A.; Greedy, B.; Lawrence, H.R.; Yip, M.L.; Jove, R.; McLaughlin, M.M.; Lawrence, N.J.; Sebti, S.M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA, 2007, 104(18), 7391-7396. (Pubitemid 47185916)
76. Zhang, S.; Zhang, Z.Y. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today, 2007, 12(9-10), 373-381. (Pubitemid 46636379)
77. Halgren, R.; Murphy, R.; Friesner, H.; Beard, L.; Frye, W.; Pollard, J.; Banks, J.L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem., 2004, 47(7), 1750- 1759. (Pubitemid 38380918)
78. Fletcher, S.; Singh, J.; Zhang, X.; Yue, P.; Page, B.D.; Sharmeen, S.; Shahani, V.M.; Zhao, W.; Schimmer, A.D.; Turkson, J.; Gunning, P.T. Disruption of transcriptionally active STAT3 dimers with nonphosphorylated, salicylic acid-based small molecules: potent in vitro tumour cell activities. Chem. Bio. Chem., 2009, 10(12), 1959-1964.
79. Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P. T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol., 2010, 79(10), 1398-1409.
80. Matsuno, K.; Masuda Y.; Uehara, Y.; Sato, H.; Muroya, A.; Takahashi, O.; Yokotagawa, T.; Furuya, T.; Okawara, T.; Otsuka, M.; Ogo, N.; Ashizawa, T.; Oshita, C.; Tai, S.; Ishii, H.; Akiyama, Y.; Asai, A. Identification of a New Series of STAT3 Inhibitors by Virtual Screening. ACS Med. Chem. Lett., 2010, 1(8), 371-375.
81. Okamoto, M.; Takayama, K.; Shimizu, T.; Ishida, K.; Takahashi, O.; Furuya, T. Identification of death-associated protein kinases inhibitors using structure-based virtual screening. J. Med. Chem., 2009, 52(22), 7323-7327.
82. Schust, J.; Sperl, B.; Hollis, A.; Mayer, T.U.; Berg, T. Stattic: a smallmolecule inhibitor of STAT3 activation and dimerization. Chem. Biol., 2006, 13(11), 1235-1242. (Pubitemid 44750735)
83. Xu, J.; Cole, D.C.; Chang, C.P.; Ayyad, R.; Asselin, M.; Hao, W.; Gibbons, J.; Jelinsky, S.A.; Saraf, K.A.; Park, K. Inhibition of the signal transducer and activator of transcription-3 (STAT3) signaling pathway by 4-oxo-1- phenyl-1,4-dihydroquinoline-3-carboxylic acid esters. J. Med. Chem., 2008, 51(14), 4115-4121. (Pubitemid 352032439)
84. Turkson, J.; Zhang, S.; Mora, L.B.; Burns, A.; Sebti, S.; Jove R. Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies. ACS Med. Chem. Lett., 2011, 13(2), 79-84.
85. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267(3), 727-748. (Pubitemid 27170693)
86. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22(47), 7265-7279. (Pubitemid 37487159)
87. Perez, J. M.; Kelland, L.R.; Montero, E.I.; Boxall, F.E.; Fuertes, M.A.; Alonso, C.; Navarro-Ranninger, C. Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)]. Mol. Pharmacol., 2003, 63(4), 933-944. (Pubitemid 36369001)
88. Bose, R. N. Biomolecular targets for platinum antitumor drugs. Mini. Rev. Med. Chem., 2002, 2(2), 103-111.
89. Allain, P.; Heudi, O.; Cailleux, A. ; Le Bouil, A.; Larra, F.; Boisdron-Celle, M.; Gamelin, E. Early biotransformation of oxaliplatin following its intravenous administration to cancer patients. Drug Metab. Dispos., 2000, 28(11), 1379-138.
90. Heudi, O.; Mercier-Jobard, S.; Cailleux, A.; Allain, P. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: A comparison with cisplatin. Biopharm. Drug Dispos., 1999, 20, 107-116. (Pubitemid 29082204)
91. Heudi, O., Brisset, H., Cailleux, A., and Allain, P. Chemical instability and methods for measurement of cisplatin adducts formed by interactions with cysteine and glutathione. Int. J. Clin. Pharmacol. Ther. 2001, 39(8), 344- 349. (Pubitemid 32707812)
92. Weidler, M.; Rether, J.; Anke, T.; Erkel, G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett., 2000, 484(1), 1-6.
93. von Nussbaum, F.; Hanke, R.; Fahrig, T.; Benet-Buchholtz, J. The highintrinsic Diels-Alder reactivity of (-)-galiellalactone; generating for quaternary carbon centers under mild conditions. Eur. J. Org. Chem., 2004, (13), 2783-2790.
94. Hellsten, R.; Johansson, M.; Dahlman, A.; Dizeyi, N.; Sterner, O.; Bjartell, A.; Hellsten, R.; Johansson, M.; Dahlman, A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate, 2008, 68(3), 269-280. (Pubitemid 351273056)
95. van Kester, M.S.; Out-Luiting, J.J.; von dem Borne, P.A.; Willemze, R.; Tensen, C.P.; Vermeer, M.H. Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells. J. Invest. Dermatol., 2008, 128(7), 1691-1695. (Pubitemid 351847375)
96. Shi, X.; Franko, B.; Frantz, C.; Amin, H.M.; Lai R. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br. J. Haematol. 2006, 135(1), 26-32. (Pubitemid 44337660)
97. Su, Y.; Li, G.; Zhang, X.; Gu, J.; Zhang, C.J.; Zhigang, T.; Zhang, J. JSI-124 Inhibits Glioblastoma Multiforme Cell Proliferation through G2/M Cell Cycle Arrest and Apoptosis Augmentation. Cancer Biol. Ther., 2008, 7(8), 1243-1249.
98. Nefedova, Y.; Nagaraj, S.; Rosenbauer, A.; Muro-Cacho, C.; Sebti, S.M.; Gabrilovich, D.I. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/ signal transducers and activators of transcription 3 pathway. Cancer Res., 2005, 65(20), 9525-35. (Pubitemid 41508023)
99. Liu, T.; Zhang, M.; Zhang, H.; Sun, C.; Yang, X.; Deng, Y.; Ji, W. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur. J. Pharmacol., 2008, 587(13), 78-84.
100. Tannin-Spitz, T.; Grossman, S.; Dovrat, S.; Gottlieb, H.E.; Bergman, M. Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem. Pharmacol., 2007, 73(1), 56-67. (Pubitemid 44853933)
101. Xiao, Z.; Hao, Y.; Liu, B.; Qian, L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk. Lymphoma 2002, 43(9), 1763-1768. (Pubitemid 34874008)
102. Merz, K. H.; Schwahn, S.; Hippe, F.; Muhlbeyer, S.; Jakobs, S.; Eisenbrand, G. Novel indirubin derivatives, promising anti-tumor agents inhibiting cyclin-dependent kinases. Int. J. Clin. Pharmacol. Ther., 2004, 42(11), 656-658.
103. Eisenbrand, G.; Hippe, F.; Jakobs, S.; Muehlbeyer, S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer Res. Clin. Oncol., 2004, 130(11), 627-635. (Pubitemid 39506375)
104. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A.S.; Carter, B.; Turkson, J.; Jove R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5(3), 621-629.
105. Meydan, N.; Grunberger, T.; Dadi, H.; Shahar, M.; Arpaia, E.; Lapidot, Z.; Leeder, J.S.; Freedman, M.; Cohen, A.; Gazit, A.; Levitzki, A.; Roifman, C.M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 1996, 379(6566), 645-648. (Pubitemid 26053453)
106. Bharti, A.C.; Donato, N.; Aggarwal, B.B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol., 2003, 171(7), 3863-3871. (Pubitemid 37254592)
107. Aggarwal, B.B.; Kumar, A.; Bharti, A.C.; Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 2003, 23(1A), 363-398. (Pubitemid 36361976)
108. Chen, S.C.; Chang, Y.L.; Wang, D.L.; Cheng, J.J. Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. Br. J. Pharmacol., 2006, 148(2), 226-232. (Pubitemid 43873041)
109. Chen, Y.H.; Lin, S.J.;. Chen, J.W.; Ku, H.H.; Chen, Y.L. Magnolol attenuates VCAM-1 expression in vivo in the aorta of cholesterol-fed rabbits. Br. J. Pharmacol., 2002, 135(1), 37-47.
110. Lee, J.; Jung, E.; Park, J.; Jung, K.; Lee, S.; Hong, S.; Park, E.; Kim, J.; Park, S.; Park, D. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NFkappaB activation signaling. Planta Med., 2005, 71(4), 338-343. (Pubitemid 40676458)